Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy
Authors:
- Joep M.A. LangeJLJoep M.A. Lange
- Suzanne JurriaansSJSuzanne Jurriaans
- Jan M. PrinsJPJan M. Prins
- Vladimir V. LukashovVLVladimir V. Lukashov
- Daan W. NotermansDNDaan W. Notermans
- Marijke RoosMRMarijke Roos
- Hanneke SchuitemakerHSHanneke Schuitemaker
- Richard M.W. HoetelmansRHRichard M.W. Hoetelmans
- Sven A. DannerSDSven A. Danner
- Jaap GoudsmitJGJaap Goudsmit
- Frank de WolfFWFrank de Wolf
- 1 July 1998
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (11) , F117-F122
Abstract
To compare the viral suppression of two antiretroviral regimens using three drugs or five drugs. Two open-label studies using a three-drug (zidovudine, lamivudine and ritonavir) and a five-drug regimen (zidovudine, lamivudine, abacavir, indinavir and nevirapine) in study-drug-naive patients, except for one in the five-drug study. Participants with ≥ 10 000 HIV-1 RNA copies/ml in plasma at baseline were compared by means of Kaplan-Meier curves for time to < 50 copies/ml, as well as linear regression analysis for the first phase of decline using log-transformed copy numbers. The elimination rate constants for HIV-1 RNA in 15 participants of the three-drug study were compared with nine participants of the five-drug study. The level of < 50 copies/ml was reached earlier when using the five-drug than when using the three-drug regimen (P log rank = 0.0005): median time to reach this level was 4 weeks and 12 weeks, respectively. No differences were found in HIV-1 RNA elimination rate constants in the first 2 weeks after the initiation of therapy. When the viral load declines were calculated from day 2 onwards, adjusting for differences in pharmacological delay of the drugs used, again no differences in early viral load decline were found between the two regimens. With the five drugs used in this study, the median time to reach < 50 HIV-1 RNA copies/ml was 8 weeks shorter than with the three-drug regimen. This finding shows that suppression of viral load in HIV-infection by standard triple-drug therapy can be improved upon.Keywords
This publication has 21 references indexed in Scilit:
- Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.Journal of Clinical Investigation, 1997
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Antiretroviral Therapy for HIV Infection in 1997JAMA, 1997
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 InfectionNew England Journal of Medicine, 1995
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cellsAntimicrobial Agents and Chemotherapy, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995